The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
REGULATORY
Proposed Introduction of Elective Care Scheme for LLP Copay “Hard to Understand”: Chuikyo Members
Japan’s key reimbursement policy panel on December 1 continued to discuss the proposed copay review of off-patent brand-name drugs, called long-listed products (LLPs), but many members complained about the complex nature of the proposal, calling for establishing an easy-to-understand system.…
To read the full story
Related Article
- MHLW Clarifies Criteria for “Medical Necessity” of LLPs before Elective Care Rollout
July 17, 2024
- Japan Unveils 1,095 Off-Patent Branded Drugs Subject to New Coverage Rule
April 23, 2024
- MHLW Defines “Long-Listed Products” towards Rollout of New Coverage Rule
April 1, 2024
- Chuikyo to Discuss Exclusion of Long-Listed Biologics from New Coverage Scheme
January 29, 2024
- Chuikyo Officially OKs Application of Elective Care for Off-Patent Branded Drugs
December 28, 2023
- Japan to Roll Out New LLP Coverage Rule in October; 18 Billion Yen Saving Eyed for FY2024
December 21, 2023
- Chuikyo Split on Copay Rate under Elective Care Scheme; Political Decision Likely over 1/2 or 1/4
December 18, 2023
- Japan Panel OKs Basic Plan for Elective Care Scheme for LLPs; 900 APIs Targeted
December 11, 2023
- Panelists Urge Exclusion of LLPs from Copay Increase If Generic Access Is Difficult
November 30, 2023
- Japan Deeping Debate on LLP Copay Review; Focus Is on Exclusion Criteria, Payment Levels, G1/G2 Rule Change
November 27, 2023
- Japan Panel Supports Certain Out-of-Pocket Payment for LLP-Generic Price Gap
November 10, 2023
- As Copay Debate Picks Up Steam, MHLW Floats 4 Ideas for Coverage Reform
October 2, 2023
- With Generics Now in Common Use, It’s Time for Debate on LLP Copay: Payers
August 4, 2023
REGULATORY
- Panel to Weigh Orphan Designation for Tecartus on December 22
December 17, 2025
- LDP League Formally Urges Male HPV Shots Under NIP from FY2026
December 17, 2025
- Solo Distribution Poses Threats to Stable Supplies, Price Negotiations: Survey
December 17, 2025
- MHLW Drafts Guideline Update, Urges Makers to Factor Distribution Costs into WPPs
December 16, 2025
- MHLW to Add Company-Driven Route to “Specific-Use Drug” Designations
December 16, 2025
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…